Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

8.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.8K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

2.7K
2.7K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

3.1K
3.1K
Allosteric Regulation01:08

Allosteric Regulation

63.4K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
63.4K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

6.6K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.6K
Positive Regulator Molecules01:45

Positive Regulator Molecules

136.5K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
136.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR.

Journal of medicinal chemistry·2026
Same author

Tips for Office Procedural Coding: Developed by the AUGS Coding Committee.

Urogynecology (Philadelphia, Pa.)·2025
Same author

Evaluation of a non-nucleoside inhibitor of the RSV RNA-dependent RNA polymerase in translatable animals models.

The Journal of infection·2024
Same author

Rapid Affinity and Microsomal Stability Ranking of Crude Mixture Libraries of Histone Deacetylase Inhibitors.

ACS medicinal chemistry letters·2024
Same author

Cerastecin Inhibition of the Lipooligosaccharide Transporter MsbA to Combat <i>Acinetobacter baumannii</i>: From Screening Impurity to <i>In Vivo</i> Efficacy.

Journal of medicinal chemistry·2024
Same author

Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis.

Clinical pharmacokinetics·2023
Same journal

Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.

ACS medicinal chemistry letters·2026
Same journal

Investigation on the Cytotoxicity of Hydroxycinnamic and Hydroxybenzoic Acid-Based Natural Antioxidant Conjugated Terpyridine Analogues toward Triple-Negative Breast Cancer.

ACS medicinal chemistry letters·2026
Same journal

Beyond Neddylation Inhibition: X‑ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat.

ACS medicinal chemistry letters·2026
Same journal

Structure-Guided Discovery of Selective Polo-Like Kinase 3 Inhibitors.

ACS medicinal chemistry letters·2026
Same journal

Controlling Neuroplasticity Across Scales: Constrained Serotonergic Agonists, Neuroplastogens, and Adaptive Neuromodulation.

ACS medicinal chemistry letters·2026
Same journal

Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer.

ACS medicinal chemistry letters·2026
See all related articles

Related Experiment Video

Updated: Feb 7, 2026

Spatiotemporal Control of Protein Activity through Optogenetic Allosteric Regulation
08:00

Spatiotemporal Control of Protein Activity through Optogenetic Allosteric Regulation

Published on: October 4, 2024

1.1K

MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate.

Douglas C Beshore1, Christina N Di Marco1, Ronald K Chang1

  • 1MRL, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.

ACS Medicinal Chemistry Letters
|July 24, 2018
PubMed
Summary
This summary is machine-generated.

Researchers optimized a drug to selectively activate the M1 muscarinic pathway, crucial for treating neurological disorders. This led to MK-7622, a positive allosteric modulator now in Phase II trials for Alzheimer's disease.

More Related Videos

Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis Infection
10:43

Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis Infection

Published on: September 18, 2020

32.5K
Polarization and Characterization of M1 and M2 Human Monocyte-Derived Macrophages on Implant Surfaces
08:37

Polarization and Characterization of M1 and M2 Human Monocyte-Derived Macrophages on Implant Surfaces

Published on: December 6, 2024

1.8K

Related Experiment Videos

Last Updated: Feb 7, 2026

Spatiotemporal Control of Protein Activity through Optogenetic Allosteric Regulation
08:00

Spatiotemporal Control of Protein Activity through Optogenetic Allosteric Regulation

Published on: October 4, 2024

1.1K
Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis Infection
10:43

Polarization of M1 and M2 Human Monocyte-Derived Cells and Analysis with Flow Cytometry upon Mycobacterium tuberculosis Infection

Published on: September 18, 2020

32.5K
Polarization and Characterization of M1 and M2 Human Monocyte-Derived Macrophages on Implant Surfaces
08:37

Polarization and Characterization of M1 and M2 Human Monocyte-Derived Macrophages on Implant Surfaces

Published on: December 6, 2024

1.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Discovery

Background:

  • Selective activation of the M1 muscarinic signaling pathway is a long-standing goal for treating neurological and cognitive disorders.
  • Developing effective treatments for Alzheimer's disease remains a significant challenge.

Purpose of the Study:

  • To optimize ligands for selective M1 muscarinic receptor activation.
  • To identify a clinical candidate with favorable physicochemical and safety profiles for Alzheimer's disease treatment.

Main Methods:

  • Iterative drug design and optimization focusing on physicochemical and safety properties.
  • Characterization of the resulting compound as a selective positive allosteric modulator of the M1 muscarinic receptor.

Main Results:

  • Successful optimization led to the identification of MK-7622.
  • MK-7622 demonstrates high selectivity for the M1 muscarinic receptor.

Conclusions:

  • MK-7622 is a promising clinical candidate for Alzheimer's disease.
  • The developed compound has advanced to Phase II clinical studies for Alzheimer's disease treatment.